Blue Yonder Acquires One Network Enterprises to Unlock an Agile, Interconnected Supply Chain Ecosystem
1.8.2024 18:12:00 EEST | Business Wire | Press release
Blue Yonder, the leader in digital supply chain transformations, today announced the closing of its acquisition of One Network Enterprises (One Network) at an enterprise value of approximately $839 million. The acquisition gives Blue Yonder customers the ability to collaborate and share data – from inventory levels to raw and finished goods materials movement – in real time across all trading partners up and down the supply chain.
With increasing volatility and continuous disruptions, retailers, manufacturers and logistics service providers (LSPs) need to achieve multi-enterprise transparency with trading partners, unify plans and actions, and conduct business in real time in order to enable more accurate cross-functional decision-making and eliminate the time gap between order planning and fulfillment. It’s no longer sufficient for companies to rely on periodic updates about their inventory, capacity, and resources; true business agility requires real-time information across an entire network.
With the addition of One Network’s commercial technology, Blue Yonder can now offer customers a multi-enterprise, multi-tier network ecosystem; artificial intelligence (AI)-powered supply chain assistants to identify, monitor, analyze, and resolve problems; and a simplified process to onboard and work with trading partners. Real-time inventory and capacity views help customers match supply and demand, detect and resolve problems, and orchestrate resources across their network of trading partners. One Network will continue to independently service and provide tailored technology solutions to its government customers.
“One Network’s industry-leading commercial technology will seamlessly be integrated into the Blue Yonder Platform. Their supply chain network and intelligent control tower deliver superpowered insights to businesses looking to fortify their supply chains,” said Duncan Angove, CEO, Blue Yonder. “Our customers can boost visibility, agility and speed thanks to a single source of truth provided by the Blue Yonder Platform and the digital network, all enhanced by our AI assistants, solvers and predictions. This allows customers to see issues both downstream and upstream in real time, so they can avoid disruptions and make better decisions. From One Network’s capabilities to its forward-looking mission, the company perfectly embodies Blue Yonder’s vision to transform the supply chain.”
With this acquisition, Blue Yonder customers will be able to address volatility and disruptions in the market, plan with greater accuracy, meet rising customer expectations, and simplify complexity within their supply chains. Blue Yonder customers will have access to the following benefits:
- Navigating increasing uncertainty and volatility with real-time visibility across multiple tiers to anticipate risks, assess scenarios, and instantly redirect resources where needed most to deliver the greatest impacts to their business and sustainability goals.
- Optimizing of resources, from capacity and inventory to workforce and carriers to better serve their business customers, capitalize on new market opportunities, and accelerate revenue growth.
- Collaborating and orchestrating of their supply chain in real-time across a global network of 150,000 (and counting) trading partners using a shared view and dataset that ensures planning objectives flow into execution and vice versa to optimize critical KPIs.
“Blue Yonder is building the supply chain of the future,” said Angove. “To succeed in today’s business environment, planning and logistics teams need to make decisions faster. They need to collaborate with more partners. They need faster responsiveness to disruptions. One Network’s multi-tier and multi-enterprise network has a large role to play here, and we’re proud to join forces with them to make a lasting difference.”
This acquisition also catalyzed Blue Yonder’s expanded presence in Dallas, where it has been hiring extensively to support its momentum. Blue Yonder is now designating Dallas as its Global Innovation Center. In May during its annual customer conference, ICON, Blue Yonder announced a new AI Innovation Studio in Dallas where the company is hosting design-led AI Agent workshops with customers. Blue Yonder also plans to add a state-of-the-art Customer Experience Center in Dallas where the company will showcase its latest innovations that are transforming complex global supply chains.
One Network is the third company Blue Yonder has acquired since Q4 2023, following Doddle in November 2023 and flexis AG in February. These deals mark approximately $1 billion in M&A investments and are emblematic of Blue Yonder’s intent to transform the global supply chain.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your PotentialTMwww.blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731317929/en/
Contacts
Blue Yonder Corporate Communications:
mediarelationsteam@blueyonder.com
U.S.: +1 480-308-3037
EMEA: +39 335 7849149
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom